Wednesday - April 22, 2026

Category Archives: Pharmaceuticals & Biotech

Focal Segmental Glomerulosclerosis Market to Surpass USD 837 Million by 2034, Growing at a Steady CAGR from USD 734 Million in 2022, Driven by Novel Therapies, Rising Prevalence | DelveInsight

Focal Segmental Glomerulosclerosis Market Key companies actively involved in the Focal Segmental Glomerulosclerosis (FSGS) market include Travere Therapeutics, Dimerix, Goldfinch Bio, Vertex Pharmaceuticals, GlaxoSmithKline, Dimerix Bioscience Pty Ltd, ChemoCentryx, AstraZeneca, Genentech, Inc., Sanofi, Mallinckrodt ARD LLC, ACELYRIN Inc., Kyowa Kirin … Continue reading →

EMPAVELI Sales Forecast to 2034 Signals Strong Growth Across PNH and Rare Kidney Diseases, Driven by C3 Inhibition Advantage and Expanding Indication Landscape | DelveInsight

EMPAVELI Sales The global rare disease therapeutics landscape is undergoing a profound transformation, and at the center of this evolution is EMPAVELI (pegcetacoplan) – a first-in-class complement C3 inhibitor that is redefining treatment paradigms across hematology and nephrology. According to … Continue reading →

Psoriatic Arthritis Market to Exceed USD 15 Billion by 2034 with 20+ Emerging Therapies and Strong Clinical Advancements from UCB Biopharma, Bristol Myers Squibb, and Sun Pharmaceutical | DelveInsight

Psoriatic Arthritis Market Leading Psoriatic Arthritis companies working in the market are UCB Biopharma, Sun Pharmaceutical Industries Limited, BMS, Affibody AB, Janssen Biotech, Amgen, Eli Lilly and Company, Teva Pharma, Boehringer Ingelheim, AbbVie, Roche, Ampio Pharmaceuticals, Antares Pharma, Currax Pharmaceuticals, … Continue reading →

Multiple Myeloma Treatment Pipeline Shows Strong Momentum as 75+ Pharma Companies in the Race | DelveInsight

DelveInsight’s “Multiple Myeloma Pipeline Insights 2026” report provides comprehensive insights about 75+ Multiple Myeloma Companies and 80+ pipeline drugs in the Multiple Myeloma pipeline landscape. It covers the Multiple Myeloma pipeline drug profiles, including clinical and nonclinical stage products. It … Continue reading →

Postherpetic Neuralgia Pipeline Set for Strategic Expansion by 2026 with Emerging Neuromodulatory Therapies and Clinical Advancements | DelveInsight

Postherpetic Neuralgia Pipeline Leading Postherpetic Neuralgia Companies include Ono Pharmaceutical Co. Ltd, Undaunted Bio, Shanghai SIMR Biotechnology Co., Ltd. and others. DelveInsight’s latest report, “Postherpetic Neuralgia Pipeline Insight, 2026,” offers comprehensive insights into 3+ companies and 3+ pipeline drugs within … Continue reading →

Wound Closure Devices Market to Reach USD 28.13 Billion by 2032, Growing at a 7.52% CAGR Driven by Rising Surgical Volumes and Advancements in Closure Technologies | DelveInsight

Wound Closure Devices Market Some of the key market players operating in the wound closure devices market include Medtronic, 3M, Johnson & Johnson Services, B. Braun Melsungen AG, Baxter, Smith & Nephew, Stryker, Chemence Medical, Healthium Medtech, Meril Life Sciences … Continue reading →

Parkinson’s Disease Pipeline Accelerates with 200+ Therapies and 150+ Companies Driving Next-Gen Innovations | DelveInsight

Parkinson’s Disease Pipeline Key Parkinson’s Disease Companies are Roche, Prothena Biosciences, Biohaven Pharmaceuticals, Neuraly Inc., Cerevance, IRLAB, Neuron23, Ventyx Biosciences, Lundbeck, Sanofi, Eli Lilly and Company, and others The Parkinson’s disease therapeutic landscape is undergoing a transformative shift as over … Continue reading →

Chronic Periodontitis Clinical Trial Pipeline Expands as 10+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s, “Chronic Periodontitis Pipeline Insight, 2026” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Chronic Periodontitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment … Continue reading →

Asthma Clinical Trial Pipeline Shows Potential with Active Contributions from 80+ Key Companies | DelveInsight

DelveInsight’s “Asthma Pipeline Insight 2026” report provides comprehensive insights about 80+ companies and 90+ pipeline drugs in the Asthma pipeline landscape. It covers the Asthma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Asthma therapeutics … Continue reading →

Graft Versus Host Disease Clinical Trial Pipeline Accelerates as 45+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s, “Graft versus host disease Pipeline Insight 2026” report provides comprehensive insights about 45+ Graft Versus Host Disease Companies and 50+ pipeline drugs in Graft versus host disease pipeline landscape. It covers the Graft Versus Host Disease pipeline drug profiles, … Continue reading →